MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset

Oral Oncology

Volumn 45, Issue 6, 2009, Pages 496-500

  Hamid, Sharifah ^a   Yang, Yi Hsin ^b   Peng, Karen Ng Lee ^c   Ismail, Siti Mazlipah ^c   Zain, Rosnah Binti ^c   Lim, Kue Peng ^a   Wan Mustafa, Wan Mahadzir ^d   Abraham, Mannil Thomas ^d   Teo, Soo Hwang ^a   Cheong, Sok Ching ^a  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d MINISTRY OF HEALTH   (Malaysia)

Author keywords

MDM2 SNP309; Oral squamous cell carcinoma; Single nucleotide polymorphism

Indexed keywords

PROTEIN MDM2;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; UPREGULATION;

AGE OF ONSET; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALAYSIA; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 67349255275     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.06.003     Document Type: Article

References (29)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 6810 (2000) 307-310
2. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 3 (1997) 323-331
3. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1 3 (2001) 233-340
4. Alt J.R., Greiner T.C., Cleveland J.L., and Eischen C.M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Embo J 22 6 (2003) 1442-1450
5. Poyurovsky M.V., and Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 20 2 (2006) 125-131
6. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., and Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95 26 (1998) 15608-15612
7. Sheikh M.S., Shao Z.M., Hussain A., and Fontana J.A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53 14 (1993) 3226-3228
8. McCann A.H., Kirley A., Carney D.N., Corbally N., Magee H.M., Keating G., et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71 5 (1995) 981-985
9. Eymin B., Gazzeri S., Brambilla C., and Brambilla E. Mdm2 overexpression and p14 (ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21 17 (2002) 2750-2761
10. Agarwal S., Mathur M., Srivastava A., and Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol 35 2 (1999) 209-216
11. Huang J.S., Ho T.J., Chiang C.P., Kok S.H., Kuo Y.S., and Kuo M.Y. MDM2 expression in areca quid chewing-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 30 1 (2001) 53-58
12. Lim K.P., Sharifah H., Lau S.H., Teo S.H., and Cheong S.C. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event. Oncol Rep 14 4 (2005) 963-968
13. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M.R., Pollack D., Woodruff J.M., et al. Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54 3 (1994) 794-799
14. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 5 (2004) 591-602
15. Hu W., Feng Z., Ma L., Wagner J., Rice J.J., Stolovitzky G., et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 67 6 (2007) 2757-2765
16. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65 20 (2005) 9582-9587
17. Park S.H., Choi J.E., Kim E.J., Jang J.S., Han H.S., Lee W.K., et al. MDM2 309T > G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 54 1 (2006) 19-24
18. Lum S.S., Chua H.W., Li H., Li W.F., Rao N., Wei J., et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29 4 (2008) 754-761
19. Wilkening S., Bermejo J.L., and Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28 11 (2007) 2262-2267
20. Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., Bono P., Arola J., Jarvinen H.J., et al. The MDM2 promoter polymorphism SNP309T > G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42 9 (2005) 694-698
21. Tu H.F., Chen H.W., Kao S.Y., Lin S.C., Liu C.J., and Chang K.W. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol (2008)
22. Hu Z., Jin G., Wang L., Chen F., Wang X., and Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16 12 (2007) 2717-2723
23. Phelps M., Darley M., Primrose J.N., and Blaydes J.P. p53-Independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 63 10 (2003) 2616-2623
24. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66 10 (2006) 5104-5110
25. Bond G.L., Menin C., Bertorelle R., Alhopuro P., Aaltonen L.A., and Levine A.J. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43 12 (2006) 950-952
26. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., and Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119 3 (2006) 718-721
27. Bougeard G., Baert-Desurmont S., Tournier I., Vasseur S., Martin C., Brugieres L., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43 6 (2006) 531-533
28. Boersma B.J., Howe T.M., Goodman J.E., Yfantis H.G., Lee D.H., Chanock S.J., et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98 13 (2006) 911-919
29. Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12 16 (2006) 4867-4871